Rapport Therapeutics (RAPP) Retained Earnings (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Retained Earnings of -$255.1 million for Q1 2026, down 72.59% year-over-year from -$930.6 million in Q1 2025, and down 46818.86% quarter-over-quarter from $546000.0 in Q4 2025.
Rapport Therapeutics (RAPP) Retained Earnings (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Retained Earnings for 4 consecutive years, with -$255.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 72.59% year-over-year to -$255.1 million; the TTM figure through Mar 2026 stood at -$255.1 million (down 72.59% YoY), while the FY2025 annual figure was $546000.0, up 204.6% from the prior year.
- Retained Earnings fell to -$255.1 million in Q1 2026 per RAPP's latest filing, from $546000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $546000.0 in Q4 2025 and bottomed at -$255.1 million in Q1 2026.
- Historically, Retained Earnings has averaged -$93.3 million across 4 years, with a median of -$86.2 million in 2024.
- On a YoY basis, Retained Earnings climbed as much as 204.6% in 2025 and fell as far as 94.16% in 2025.
- Rapport Therapeutics' Retained Earnings stood at -$45.4 million in 2023, then soared by 98.85% to -$522000.0 in 2024, then surged by 204.6% to $546000.0 in 2025, then tumbled by 46818.86% to -$255.1 million in 2026.
- Business Quant data shows RAPP's Retained Earnings at -$255.1 million in Q1 2026, $546000.0 in Q4 2025, and -$201.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | -311.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -311.70 Mn |
| Mar 31, 2026 | -255.09 Mn |
| Dec 31, 2025 | 546,000.00 |
| Sep 30, 2025 | -201.47 Mn |
| Jun 30, 2025 | -76,000.00 |
| Mar 31, 2025 | -147.80 Mn |
| Dec 31, 2024 | -522,000.00 |
| Sep 30, 2024 | -103.77 Mn |
| Jun 30, 2024 | -86.20 Mn |
| Dec 31, 2023 | -45.44 Mn |